Fibronostics is a Singapore and New York–based diagnostics company that develops non-invasive, algorithmic tests to detect and manage organ lesions caused by metabolic diseases. Its core product, LIVERFASt, is a patented blood test that combines AI and broadly available biomarkers to precisely stage liver lesions and diagnose liver disease. LIVERFASt is commercialized in North America, Asia, Europe and LATAM and has screened more than 70K patients. The company also uses AI to screen and measure progression and prognosis of kidney disease and other chronic conditions and offers a cloud platform for integration with healthcare providers. The Series A financing will accelerate commercialization of LIVERFASt in the U.S. and fund expansion of its SaaS platform with new products targeting COVID-19, kidney and lung diseases. Led by CEO Roni Amiel, Fibronostics plans to broaden its diagnostic offerings and deepen provider integration.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2020